Advanced searches left 3/3

Cardiac Myosin Binding Protein - Crossref

Summarized by Plex Scholar
Last Updated: 16 August 2022

* If you want to update the article please login/register

The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability

We presented the pathogenic W792R mutation in mouse cardiomyocytes lacking endogenous cMyBP-C mishaps on contractile function in mouse cardiomyocytes lacking endogenous cMyBP-C mutants with a three-dimensional engineered cardiac tissue constructs to gain insight into the effects of disease-causing cMyBP-C missense mutations on contractile function and investigated the functional effects using three-dimensional engineered cardiac tissue constructs in order to gain insight into the effect on cardiac muscle cMyBP-C missense mutation in mouse cardiomyocytes lacking endogenous cMyBP-C missense cMyBP-C missense mutations lacking endogenous cMyBP-C missense mutations on cardiac muscle function. With Adenoviral transduction of wild-type and W792R cDNA, equivalent mRNA transcript abundance was achieved but not equivalent protein levels were obtained, but not with W792R compared to WT controls. W792R-expressing W792R had abnormal contraction kinetics in comparison to WT mECTs that were virtually identical to cMyBP-C-deficient mECTs. Inhibition of both ubiquitin-proteasome and lysosomal degradation pathways was found to be responsible for W792R cMyBP-C's rapid depletion of W792R cMyBP-C. Inhibition of both ubiquitin-proteasome and lysosomal degradation pathways in an increase in full-length mutant protein abundance to WT equivalence is slow, resulting in rapid cytosoli This report details the vulnerability of FnIII-like domains to mutations that alter domain stability, as well as the fact that missense mutations in cMyBP-C can cause disease through a mechanism of haploinsufficiency.

Source link: https://doi.org/10.1152/ajpheart.00686.2017


Transcriptome Profile Identifies Actin as an Essential Regulator of Cardiac Myosin Binding Protein C3 Hypertrophic Cardiomyopathy in a Zebrafish Model

Variants in cardiac myosin-binding protein C are the leading cause of inherited hypertrophic cardiomyopathy, according to genetic mutations of inherited hypertrophic cardiomyopathy, revealing the key role that cMyBP-C plays in the main body of the nation's contractile machinery. Both the mypbc3 heterozygous and homozygous groups discovered a thickened ventricular wall with reduced heart rate, swimming speed, and endurance endurance. Further, heart transcriptome profiling revealed a significant decline in the actin-filament-based process, indicating an ineffective actin cytoskeleton organization as the key dysregulating factor associated with early ventricular cardiac hypertrophy in the zebrafish mypbc3 HCM model.

Source link: https://doi.org/10.3390/ijms23168840


Investigation of Mutant Cardiac Myosin-Binding Protein C gene (MYBPC3) & Potential Cardiomyopathy Risks Among Indian Athletes

Hypertrophic Cardiomyopathy is inherited in an autosomal dominant manner, and mutation in the MYBPC3 gene has been attributed to an elevated risk of HCM and other cardiomyopathies in the South Asian population. Therefore, we investigated the prevalence of MYBPC3 d25bp variant and its familial inheritance among Indian athletes, as well as the presence of HCM phenotypes among MYBPC3 d25bp genotype carrier athletes. Methods Oral mouthwash samples were obtained from a total of 149 athletes and tested for MYBPC3 d25bp genotype as well as family members of 03 MYBPC3 d25bp heterozygous genotype carrier athletes. Conclusion Although none of the athletes displayed signs of HCM or other cardiomyopathy during study, concentric LVH and the presence of genetic variations also warrants further investigation to distinguish between physiological training-associated cardiac adaptations and pathological LV parameters, as well as mitigation of SCD/SCA risks.

Source link: https://doi.org/10.21203/rs.3.rs-1916868/v1


Modulation of Myosin by Cardiac Myosin Binding Protein-C Peptides Improves Cardiac Contractility in Ex-Vivo Experimental Heart Failure Models

Although reduced phosphorylation of cMyBP-C has been attributed to poor heart failure patients, cardiac function has not been shown to improved cardiac performance, no studies have been published on how to improve cardiac function. To investigate the role of cMyBP-C in modulating cardiac contraction and relaxation in experimental heart failure models in vitro, we used previously published cMyBP-C peptides 302A and 302S as tool molecules. Pepty muscle fiber fibers isolated from a cMyBP-C phospho-ablation mouse model were able to expand the contractility of papillary muscle fibers isolated from a cMyBP-C phosphorescence mouse model. cMyBP-C peptides isolated from MI rats isolated from MI rats, but not from sham rats, according to above results. Therefore, targeting cMyBP-C can be a differentiated strategy to raise overall cardiac health in HF patients over top of conventional care products.

Source link: https://doi.org/10.21203/rs.3.rs-955920/v1


Double heterozygosity for mutations in the β-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy

Familial hypertrophic cardiomyopathy is a genetically heterogeneous autosomal dominant disease characterized by mutations in many sarcomeric protein genes. So far, seven genes have been found to be associated with the disease, with the u03b2-myosin heavy chain and the cardiac myosin binding protein C genes being the most common. We performed electrocardiography and echocardiography in 15 people with hypertrophic cardiomyopathy from a French Caribbean family. Genomic DNA was determined by haplotype analysis with microsatellite markers at every locus concerned, as well as mutation testing by single strand conformation polymorphism analysis. Two new mutations cosegregating with the disease were discovered, one in the MYH7 gene exon 15 and the other in the MYBPC3 gene exon 30. Two of the four tested subjects had the MYH7 gene mutation, two the MYBPC3 gene mutation, and two were doubly heterozygous for the two mutations.

Source link: https://doi.org/10.1136/jmg.36.7.542


Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes

The aim of this research was to describe natural history and clinical findings in a large population of children with HCM and pathogenic/likely pathogenic MYBPC3 variants. Methods and findings Longitudinal results from 62 consecutive patients with HCM under 18 years of age and carrying at least one P/LP MYBPC3 variant were collected from a single specialist referral center, with 62 consecutive patients diagnosed with HCM under 18 years of age and carrying at least one P/LP MYBPC3 variant. Twenty patients had signs of ventricular arrest, with six patients presenting with out-of-hospital cardiac arrest. According to MACE, there were 95. 2% and 68. 4% versus MACE for those with a single or two MYBPC3 variations, respectively. The results in this cohort differ significantly from aetiologically and genetically mixed paediatric HCM cohorts described earlier, underscoring the importance of identifying specific genetic subtypes for pediatric HCM management.

Source link: https://doi.org/10.1136/jmedgenet-2021-107774

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions